3 weeks Zacks Initiates Coverage of ImmuCell With Neutral Recommendation Zacks
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates ImmuCell as “Neutral.” Explore ImmuCell’s market leadership, growth prospects and the game-changing potential of its mastitis treatment nearing FDA approval.
X